PDCD1 and cancer: The stirring CheckMate274 study presented by Dean Bajorin at the 2021 ASCO Genitourinary Cancers Symposium indicated that the adjuvant nivolumab, a PD-1 immune checkpoint inhibitor, significantly improved DFS in patients with high-risk MIUC after radical surgery, especially in PD-L1≥1% patients.